Pharmaceutical applications of poly-cationic resin

A polycationic resin and drug technology, applied in the field of medicine, can solve the problem of no treatment method and the like

Active Publication Date: 2016-12-07
SQ BIOPHARMA INC
View PDF12 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

There is no specific treatment for non-alcoholic steatohepat

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical applications of poly-cationic resin
  • Pharmaceutical applications of poly-cationic resin
  • Pharmaceutical applications of poly-cationic resin

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0101] Embodiment 1, the establishment of metabolic syndrome disease model and the control of body weight by polystyrene quaternary ammonium treatment

[0102] Under the double-whammy condition of high-fat diet and vitamin D deficiency (HFD+VDD), mice develop typical symptoms of metabolic syndrome. In the background section we described the mechanism of metabolic syndrome. It is generally believed that a high-calorie (high-fat, high-sugar) diet is an important cause of metabolic syndrome. At the same time, a large number of clinical studies and animal experiments have shown that in addition to high calorie, a "second hit" is needed to convert common fatty liver into steatohepatitis (NASH). Our recent work showed that vitamin D deficiency (VDD) can effectively promote steatohepatitis induced by a high-fat diet [25]. The vitamin D (VD3, 1000IU / kg, ANI93 standard feed) contained in the normal feed can effectively inhibit the fatty liver caused by the high-fat diet. Under the c...

Embodiment 2

[0122] Embodiment 2, polystyrene quaternary ammonium treatment controls blood sugar tolerance

[0123] Fasting blood glucose and glucose intolerance are one of the main symptoms of metabolic syndrome. Continuously elevated fasting blood sugar is the main driving force for the formation of fatty liver. Blood sugar intolerance is one of the important indicators of diabetes. Describes failures and obstructions in the delivery of insulin to the system. Such as image 3 As shown, the degree of blood sugar intolerance can be measured by measuring the body's blood sugar tolerance curve (IPGTT / AUC). After the model mice were fasted for 6 hours, a certain dose of glucose was injected intraperitoneally, and the blood glucose tolerance curve was measured. On a high-fat vitamin D-deficient diet, mice developed typical blood sugar intolerance. High-fat diet plus vitamin D deficiency can effectively increase fasting blood sugar; at the same time, blood sugar tolerance experiments also ...

Embodiment 3

[0129] Embodiment 3, polystyrene quaternary ammonium treatment reduces intra-abdominal fat content

[0130]Another important indicator of metabolic syndrome is central obesity (central obese), and a large accumulation of abdominal fat. Central obesity is manifested in increased abdominal fat content, thicker waist circumference, and increased blood lipids. Different from subcutaneous fat, abdominal fat is the main tissue that produces systemic inflammation. There are a large number of innate immune cells in abdominal fat tissue, such as macrophages (macrophages) are the main tissue that produces TNF-alpha. Persistent systemic inflammation is the main cause of insulin resistance. Therefore, persistent low-grade inflammation, insulin resistance, makes blood sugar rise; glucose in blood cannot enter target organs, including skeletal muscle, subcutaneous fat tissue. As a result, a large amount of glucose enters the liver, and the glucose in the liver can be converted into fatty ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Molecular weightaaaaaaaaaa
Login to view more

Abstract

The invention relates to pharmaceutical applications of poly-cationic resin and is based on treatment on metabolic diseases due to intestinal flora disorder by orally taking the poly-cationic resin, wherein the metabolic diseases include but not limit to: 1) non-alcoholic fatty liver, nonalcoholic steatohepatitis, hepatic fibrosis caused by intestinal bacterial toxin; 2) diabetes type II; 3) central obesity metabolic syndromes; 4) endotoxemia; etc.

Description

technical field [0001] The invention belongs to the field of medicine, and in particular relates to the pharmaceutical application of polycationic resins. Background technique [0002] 1. The prevalence and etiology of diabetes and metabolic syndrome [0003] With the rapid development of social economy, lifestyle changes, changes in diet structure, and environmental pollution have created huge social health challenges around the world. For example, fatty liver, diabetes, obesity and other metabolic disorders are becoming more and more popular. Metabolic syndrome (metabolic syndromes), or X-syndrome is a large group of diseases. Manifested as obesity, hyperglycemia, hyperlipidemia, insulin resistance (insulin resistance), type 2 diabetes, fatty liver [1]. Although fatty liver is closely related to metabolic syndrome, patients with fatty liver do not necessarily have the appearance of obesity. In the obese population, more than 60-90% of individuals have fatty liver in va...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/785A61K31/787A61P3/10A61P1/16A61P29/00A61P1/00A61P3/04A61P3/00
CPCA61K31/785A61K31/787
Inventor 韩源平朱爱如
Owner SQ BIOPHARMA INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap